Top Markets
#1 Velas Velas +562.78%
#2 Polymath Polymath +529.94%
#3 Galxe Galxe +96.05%
#4 XION XION +63.34%
#5 Resolv wstUSR Resolv wstUSR +59.11%
#6 Nomina Nomina +45.78%
#7 Cofinex Cofinex +26.87%
#8 Swarms Swarms +16.74%
#9 Unibase Unibase +15.72%
#10 Cysic Cysic +14.51%
Coin of the day
Velas Velas
Settings
Language
ENGLISH
Currency
USD
Theme
Exscientia plc Exscientia plc

Exscientia plc

EXAI
Rank in Stocks #99999
Exscientia plc, an artificial intelligence-driven pharmatech company, engages... Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Share Price
$4.84
Market Cap
$633.18M
Change (1 day)
3.20%
Change (1 year)
0.00%
Country
GB
Trade Exscientia plc (EXAI)

Category

Healthcare
Revenue for Exscientia plc (EXAI)
Revenue in Sep 2024 TTM: $22.84M
According to Exscientia plc latest financial reports the company's current revenue (TTM) is $22.84M. In 2022 the company made a revenue of $32.45M an increase over the revenue in the year 2021 that was $27.48M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exscientia plc from 2019 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $22.84M -10.65%
2023 $25.56M -21.22%
2022 $32.45M 18.10%
2021 $27.48M 52.46%
2020 $18.02M 13.81%
2019 $15.83M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 211,977.34%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 52,609.70%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 62,699.87%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 39,666.39%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 68,621.02%
AU